Fennec reports Q1 earnings per share of $0.01 and revenue growth of 72.7% year-over-year, exceeding analyst expectations.
Fennec Pharmaceuticals posted first-quarter GAAP earnings per share of $0.01, beating estimates by $0.04. Revenue reached $15.11 million, a 72.7% increase from the same period last year and $1.27 million above forecasts.
The company’s cash and cash equivalents rose to $40.1 million as of March 31, 2026, up from $36.8 million at the end of December 2025. Analysts had anticipated lower revenue and earnings for the quarter.
Shares may react positively to the stronger-than-expected financial performance and year-over-year growth.